

Intensive Control Offers Little Benefit for Vision

BY SARA FREEMAN
Contributing Writer

ROME — Eye and renal complications were no less frequent in older, difficult-to-treat patients with type 2 diabetes who were randomized to intensive rather than standard glucose control in the Veterans Affairs Diabetes Trial.

Furthermore, there was no difference between the two treatment approaches in the development of any new diabetic neu-

ropathy, according to results presented at the annual meeting of the European Association for the Study of Diabetes.

These latest findings from the 7.5-year trial followed on from the primary end point data presented at the American Diabetes Association meeting in May 2008 just 8 days after the trial had ended. The latter showed that there was no difference between intensive and standard lowering of glycated hemoglobin A_{1c} (HbA_{1c}) in terms of overall cardiovascular protection.

The two cochairs of the Veterans Affairs Diabetes Trial (VADT)—Dr. William C. Duckworth, of the Veterans Affairs Medical Center in Phoenix, and Dr. Carlos Abraira of the Miami Veterans Affairs Medical Center—discussed the new secondary outcomes data.

Compared with standard glucose control, the intensive approach was associated with nonsignificant differences in the number of new eye procedures, which included cataract surgery (10.2% vs. 11.6%),

photocoagulation (8.8% vs. 7%), and vitrectomy (3% vs. 3.3%).

“There were no differences in proliferative diabetic retinopathy or macular edema,” said Dr. Abraira, and “no difference in new onset of retinopathy.”

However, he noted that slightly more patients in the intensive therapy arm, compared with the standard control arm, required laser eye surgery overall (8.3/100 patients per year vs. 7.5/100 patients per year). In addition, the percentage of patients who developed retinopathy early—defined as a two-step increase in the Early Treatment Diabetic Retinopathy Study scale—was marginally higher in the less intensively treated patients than in the intensively treated controls (22.1% vs. 17%).

With regards to kidney complications, Dr. Abraira said that the decline in renal function was similar in both groups of patients, and severe renal disease—evidenced



‘There were no differences in proliferative diabetic retinopathy or macular edema.’

DR. ABRAIRA

by doubling of serum creatinine, serum creatinine greater than 3 mg/dL, or end-stage renal disease—was “unaffected by glucose control.”

Having a prior cardiovascular event, being a smoker, or having microalbuminuria or retinopathy at baseline were expected predictors of progression to macroalbuminuria, said Dr. Abraira. While progression from normal or microalbuminuria to overt proteinuria did not differ between standard and intensive glucose control, there was a significant decrease in progression from normal to micro- or macroalbuminuria in the intensively treated patients (31% vs. 38% for standard control, $P = .02$).

Dr. Abraira also showed that the percentage of patients in the standard vs. intensive treatment arms with neuropathy was similar: any neuropathy, 43.8% vs. 43.5%; mononeuropathy, 4% vs. 4.7%; and peripheral neuropathy, 40% vs. 38.4%. However, there was a slightly higher percentage of patients in the intensive glucose control arm that developed autonomic neuropathy (8.2% vs. 5.2%) though this was not significantly different.

Dr. Duckworth pointed out that the 1,791 patients enrolled in the VADT were a difficult-to-treat group, with a mean age of 60 years and a median duration of diabetes of 11.5 years. The mean HbA_{1c} at the start of the trial was 9.4% and fell to a median of 8.4% in the standard glucose control arm and 6.9% in the intensive glucose control arm.

Importantly, patients in the trial achieved good blood pressure control and “almost ideal” levels of LDL cholesterol and other lipids, Dr. Duckworth said. This suggests that in the presence of optimal risk factor management, it does little to add intensive glucose control in terms of the overall benefits that can be achieved.

LOVAZA®

(omega-3-acid ethyl esters) Capsules

The following is a brief summary only; see full prescribing information for complete product information.
CLINICAL STUDIES: High Triglycerides: Add-on to HMG-CoA reductase inhibitor therapy: The effects of LOVAZA 4 g per day as add-on therapy to treatment with simvastatin were evaluated in a randomized, placebo-controlled, double-blind, parallel-group study of 254 adult patients (122 on LOVAZA and 132 on placebo) with persistent high triglycerides (200 to 499 mg/dL) despite simvastatin therapy (Table 1). Patients were treated with open-label simvastatin 40 mg per day for 8 weeks prior to randomization to control their LDL-C to no greater than 10% above NCEP ATP III goal and remained on this dose throughout the study. Following 8 weeks of open-label treatment with simvastatin, patients were randomized to either LOVAZA 4 g per day or placebo for an additional 8 weeks with simvastatin co-therapy. The median baseline triglyceride and LDL-C levels in these patients were 268 mg/dL and 89 mg/dL, respectively. Median baseline non-HDL-C and HDL-C levels were 138 mg/dL and 45 mg/dL, respectively. The changes in the major lipoprotein lipid parameters for the groups receiving LOVAZA plus simvastatin and placebo plus simvastatin are shown in Table 1.

Table 1. Response to the Addition of LOVAZA 4 g per day to On-going Simvastatin 40 mg per day Therapy in Patients With High Triglycerides (200 to 499 mg/dL)

Parameter	LOVAZA + Simvastatin N = 122			Placebo + Simvastatin N = 132			Difference	P-Value
	BL	EOT	Median % Change	BL	EOT	Median % Change		
Non-HDL-C	137	123	-9.0	141	134	-2.2	-6.8	<0.0001
TG	268	182	-29.5	271	260	-6.3	-23.2	<0.0001
TC	184	172	-4.8	184	178	-1.7	-3.1	<0.05
VLDL-C	52	37	-27.5	52	49	-7.2	-20.3	<0.05
Apo-B	86	80	-4.2	87	85	-1.9	-2.3	<0.05
HDL-C	46	48	+3.4	43	44	-1.2	+4.6	<0.05
LDL-C	91	88	+0.7	88	85	-2.8	+3.5	=0.05

BL = Baseline (mg/dL); EOT = End of Treatment (mg/dL); Median % Change = Median Percent Change from Baseline; Difference = LOVAZA Median % Change - Placebo Median % Change

LOVAZA 4 g per day significantly reduced non-HDL-C, TG, TC, VLDL-C, and Apo-B levels and increased HDL-C and LDL-C from baseline relative to placebo.
Very High Triglycerides: Monotherapy: The effects of LOVAZA 4 g per day were assessed in 2 randomized, placebo-controlled, double-blind, parallel-group studies of 84 adult patients (42 on LOVAZA, 42 on placebo) with very high triglyceride levels (Table 2). Patients whose baseline triglyceride levels were between 500 and 2,000 mg/dL were enrolled in these 2 studies of 6 and 16 weeks' duration. The median triglyceride and LDL-C levels in these patients were 792 mg/dL and 100 mg/dL, respectively. Median HDL-C level was 23.0 mg/dL. The changes in the major lipoprotein lipid parameters for the groups receiving LOVAZA or placebo are shown in Table 2.

Table 2. Median Baseline and Percent Change From Baseline in Lipid Parameters in Patients With Very High TG Levels (≥500 mg/dL)

Parameter	LOVAZA N = 42		Placebo N = 42		Difference
	BL	% Change	BL	% Change	
TG	816	-44.9	788	+6.7	-51.6
Non-HDL-C	271	-13.8	292	-3.6	-10.2
TC	296	-9.7	314	-1.7	-8.0
VLDL-C	175	-41.7	175	-0.9	-40.8
HDL-C	22	+9.1	24	0.0	+9.1
LDL-C	89	+44.5	108	-4.8	+49.3

BL = Baseline (mg/dL); % Chg = Median Percent Change from Baseline; Difference = LOVAZA Median % Change - Placebo Median % Change

LOVAZA 4 g per day reduced median TG, VLDL-C, and non-HDL-C levels and increased median HDL-C from baseline relative to placebo. Treatment with LOVAZA to reduce very high TG levels may result in elevations in LDL-C and non-HDL-C in some individuals. Patients should be monitored to ensure that the LDL-C level does not increase excessively.

The effect of LOVAZA on the risk of pancreatitis in patients with very high TG levels has not been evaluated. The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated TG levels has not been determined.

INDICATIONS AND USAGE: Very High Triglycerides: LOVAZA is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with very high (≥500 mg/dL) triglyceride levels.

Usage Considerations: In individuals with hypertriglyceridemia (HTG), excess body weight and excess alcohol intake may be important contributing factors and should be addressed before initiating any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, (such as hypothyroidism or diabetes mellitus) should be looked for and adequately treated. Estrogen therapy, thiazide diuretics, and beta blockers are sometimes associated with massive rises in plasma TG levels. In such cases, discontinuation of the specific etiologic agent, if medically indicated, may obviate the need for specific drug therapy for HTG.

The use of lipid-regulating agents should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use lipid-regulating agents, the patient should be advised that use of lipid-regulating agents does not reduce the importance of adhering to diet (see PRECAUTIONS).

CONTRAINDICATIONS: LOVAZA is contraindicated in patients who exhibit hypersensitivity to any component of this medication.

PRECAUTIONS: General: Initial Therapy: Laboratory studies should be performed to ascertain that the patient's TG levels are consistently abnormal before instituting therapy with LOVAZA. Every attempt should be made to control serum TG levels with appropriate diet, exercise, weight loss in overweight patients, and control of any medical problems (such as diabetes mellitus and hypothyroidism) that may be contributing to the patient's TG abnormalities. Medications known to exacerbate HTG (such as beta blockers, thiazides, and estrogens) should be discontinued or changed, if possible, before considering TG-lowering drug therapy.

Continued Therapy: Laboratory studies should be performed periodically to measure the patient's TG levels during therapy with LOVAZA. Therapy with LOVAZA should be withdrawn in patients who do not have an adequate response after 2 months of treatment.

Information for Patients: LOVAZA should be used with caution in patients with known sensitivity or allergy to fish. Patients should be advised that use of lipid-regulating agents does not reduce the importance of adhering to diet.

Laboratory Tests: In some patients, increases in alanine aminotransferase (ALT) levels without a concurrent increase in aspartate aminotransferase (AST) levels were observed. Alanine aminotransferase levels should be monitored periodically during therapy with LOVAZA.

In some patients, LOVAZA increased low-density lipoprotein cholesterol (LDL-C) levels. As with any lipid-regulating product, LDL-C levels should be monitored periodically during therapy with LOVAZA.

Drug Interactions: Anticoagulants: Some studies with omega-3-acids demonstrated prolongation of bleeding time. The prolongation of bleeding time reported in these studies has not exceeded normal limits and did not produce clinically significant bleeding episodes. Clinical studies have not been done to thoroughly examine the effect of LOVAZA and concomitant anticoagulants. Patients receiving treatment with both LOVAZA and anticoagulants should be monitored periodically.

HMG-CoA reductase inhibitors: In a 14-day study of 24 healthy adult subjects, daily co-administration of simvastatin 80 mg with LOVAZA 4 g did not affect the extent (AUC) or rate (C_{max}) of exposure to simvastatin or the major active metabolite, beta-hydroxy simvastatin at steady state.

Cytochrome P450-Dependent Monooxygenase Activities: Omega-3-fatty acid containing products have been shown to increase hepatic concentrations of cytochrome P450 and activities of certain P450 enzymes in rats. The potential of LOVAZA to induce P450 activities in humans has not been studied.

Carcinogenesis, Mutagenesis, Impairment of Fertility: In a rat carcinogenicity study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated with omega-3-acid ethyl esters for 101 weeks

and females for 89 weeks without an increased incidence of tumors (up to 5 times human systemic exposures following an oral dose of 4 g/day based on a body surface area comparison). Standard lifetime carcinogenicity bioassays were not conducted in mice.

Omega-3-acid ethyl esters were not mutagenic or clastogenic with or without metabolic activation in the bacterial mutagenesis (Ames) test with *Salmonella typhimurium* and *Escherichia coli* or in the chromosomal aberration assay in Chinese hamster V79 lung cells or human lymphocytes. Omega-3-acid ethyl esters were negative in the *in vivo* mouse micronucleus assay.

In a rat fertility study with oral gavage doses of 100, 600, and 2,000 mg/kg/day, males were treated for 10 weeks prior to mating and females were treated for 2 weeks prior to and throughout mating, gestation, and lactation. No adverse effect on fertility was observed at 2,000 mg/kg/day (5 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

Pregnancy Category C: There are no adequate and well-controlled studies in pregnant women. It is unknown whether LOVAZA can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. LOVAZA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Omega-3-acid ethyl esters have been shown to have an embryocidal effect in pregnant rats when given in doses resulting in exposures 7 times the recommended human dose of 4 g/day based on a body surface area comparison.

In female rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day beginning 2 weeks prior to mating and continuing through gestation and lactation, no adverse effects were observed in the high dose group (5 times human systemic exposure following an oral dose of 4 g/day based on body surface area comparison).

In pregnant rats given oral gavage doses of 1,000, 3,000, and 6,000 mg/kg/day from gestation day 6 through day 15, no adverse effects were observed (14 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

In pregnant rats given oral gavage doses of 100, 600, and 2,000 mg/kg/day from gestation day 14 through lactation day 21, no adverse effects were seen at 2,000 mg/kg/day (5 times the human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison). However, decreased live births (20% reduction) and decreased survival to postnatal day 4 (40% reduction) were observed in a dose-ranging study using higher doses of 3,000 mg/kg/day (7 times the human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

In pregnant rabbits given oral gavage doses of 375, 750, and 1,500 mg/kg/day from gestation day 7 through day 19, no findings were observed in the fetuses in groups given 375 mg/kg/day (2 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison). However, at higher doses, evidence of maternal toxicity was observed (4 times human systemic exposure following an oral dose of 4 g/day based on a body surface area comparison).

Nursing Mothers: It is not known whether omega-3-acid ethyl esters are excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when LOVAZA is administered to a woman who is breastfeeding.

Pediatric Use: Safety and effectiveness in pediatric patients under 18 years of age have not been established.

Geriatric Use: A limited number of patients older than 65 years were enrolled in the clinical studies. Safety and efficacy findings in subjects older than 60 years did not appear to differ from those of subjects younger than 60 years.

ADVERSE REACTIONS: Treatment-emergent adverse events reported in at least 1% of patients treated with LOVAZA 4 g per day or placebo during 8 randomized, placebo-controlled, double-blind, parallel-group studies for HTG are listed in Table 3. Adverse events led to discontinuation of treatment in 3.5% of patients treated with LOVAZA and 2.6% of patients treated with placebo.

Table 3. Adverse Events in Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Studies for Very High TG Levels (≥500 mg/dL) That Used LOVAZA 4 g per Day

BODY SYSTEM Adverse Event	LOVAZA (N = 226)		Placebo* (N = 228)	
	n	%	n	%
Subjects with at least 1 adverse event	80	35.4	63	27.6
Body as a whole				
Back pain	5	2.2	3	1.3
Flu syndrome	8	3.5	3	1.3
Infection	10	4.4	5	2.2
Pain	4	1.8	3	1.3
Cardiovascular				
Angina pectoris	3	1.3	2	0.9
Digestive				
Dyspepsia	7	3.1	6	2.6
Eructation	11	4.9	5	2.2
Skin				
Rash	4	1.8	1	0.4
Special senses				
Taste perversion	6	2.7	0	0.0

Adverse events were coded using COSTART, version 5.0. Subjects were counted only once for each body system and for each preferred term.

*Placebo was corn oil for all studies.

Additional adverse events reported by 1 or more patients from 22 clinical studies for HTG are listed below:
Body as a Whole: Enlarged abdomen, asthenia, body odor, chest pain, chills, suicide, fever, generalized edema, fungal infection, malaise, neck pain, neoplasm, rheumatoid arthritis, and sudden death.

Cardiovascular System: Arrhythmia, bypass surgery, cardiac arrest, hyperlipidemia, hypertension, migraine, myocardial infarct, myocardial ischemia, occlusion, peripheral vascular disorder, syncope, and tachycardia.

Digestive System: Anorexia, constipation, dry mouth, dysphagia, colitis, fecal incontinence, gastritis, gastroenteritis, gastrointestinal disorder, increased appetite, intestinal obstruction, melena, pancreatitis, tenesmus, and vomiting.

Hematologic-Lymphatic System: Lymphadenopathy.

Infections and Infestations: Viral infection.

Metabolic and Nutritional Disorders: Edema, hyperglycemia, increased ALT, and increased AST.

Musculoskeletal System: Arthralgia, arthritis, myalgia, pathological fracture, and tendon disorder.

Nervous System: Central nervous system neoplasia, depression, dizziness, emotional lability, facial paralysis, insomnia, vasodilatation, and vertigo.

Respiratory System: Asthma, bronchitis, increased cough, dyspnea, epistaxis, laryngitis, pharyngitis, pneumonia, rhinitis, and sinusitis.

Skin: Alopecia, eczema, pruritus, and sweating.

Special Senses: Cataract.

Urogenital System: Cervix disorder, endometrial carcinoma, epididymitis, and impotence.

DRUG ABUSE AND DEPENDENCE: LOVAZA does not have any known drug abuse or withdrawal effects.

OVERDOSAGE: In the event of an overdose, the patient should be treated symptomatically, and general supportive care measures instituted, as required.

Distributed by:



GlaxoSmithKline
Research Triangle Park, NC 27709
©2008 GlaxoSmithKline. All rights reserved.
June 2008

LVZ:1BR5